Empowered Patient Podcast Karen Jagoda

Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant.  The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and OSE aims to re-educate these cells to recognize and eliminate cancer cells or restore immune tolerance in autoimmune diseases. He also discusses the potential of cancer vaccines in re-educating the immune system to target cancer cells, and the importance of combination therapies in improving treatment outcomes.
Nicolas explains, "There are two big families in the immune system. We have the adaptive immunity generated by lymphocytes. We have several types of lymphocytes: T-lymphocytes, B-lymphocytes, and so on. This is a very specific immune response that humans and other species have developed to recognize, very specifically some antigens from viruses, for tumors, and so on. We can control these cells."
"On the other side, there is innate immunity composed of macrophages, NK cells, or others, and this is a non-specific immune response that recognizes either danger signals or pathogen signals. These are mostly the elements that are implicated in many chronic inflammatory diseases. Still, there are also some elements that we can manipulate or re-educate in oncology to help the immune system globally work better. Because these lymphocytes and these macrophages, this adaptive immunity or innate immunity, work together, and all together, we can re-educate and orchestrate this immune response in a good direction."
 "There's a big promise and big hope now in the field of therapeutic cancer vaccines. It's important to understand that it's therapeutic. It means we're not yet able to prevent cancer development, this might be in the future, but we use cancer vaccines to re-educate the immune system of patients that have developed a tumor. It's a therapeutic drug, and we're developing one of the most advanced therapeutic cancer vaccines in the world with the upcoming new registration phase three in lung cancer patients in second line."
#OSEImmunotherapeutics #Cancer #LungCancer #CancerVaccine #ImmuneSystem #Macrophages #Inflammation #InflammatoryDisease

ose-immuno.com
Listen to the podcast here

Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant.  The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and OSE aims to re-educate these cells to recognize and eliminate cancer cells or restore immune tolerance in autoimmune diseases. He also discusses the potential of cancer vaccines in re-educating the immune system to target cancer cells, and the importance of combination therapies in improving treatment outcomes.
Nicolas explains, "There are two big families in the immune system. We have the adaptive immunity generated by lymphocytes. We have several types of lymphocytes: T-lymphocytes, B-lymphocytes, and so on. This is a very specific immune response that humans and other species have developed to recognize, very specifically some antigens from viruses, for tumors, and so on. We can control these cells."
"On the other side, there is innate immunity composed of macrophages, NK cells, or others, and this is a non-specific immune response that recognizes either danger signals or pathogen signals. These are mostly the elements that are implicated in many chronic inflammatory diseases. Still, there are also some elements that we can manipulate or re-educate in oncology to help the immune system globally work better. Because these lymphocytes and these macrophages, this adaptive immunity or innate immunity, work together, and all together, we can re-educate and orchestrate this immune response in a good direction."
 "There's a big promise and big hope now in the field of therapeutic cancer vaccines. It's important to understand that it's therapeutic. It means we're not yet able to prevent cancer development, this might be in the future, but we use cancer vaccines to re-educate the immune system of patients that have developed a tumor. It's a therapeutic drug, and we're developing one of the most advanced therapeutic cancer vaccines in the world with the upcoming new registration phase three in lung cancer patients in second line."
#OSEImmunotherapeutics #Cancer #LungCancer #CancerVaccine #ImmuneSystem #Macrophages #Inflammation #InflammatoryDisease

ose-immuno.com
Download the transcript here

Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection options to accommodate different lab processes and sample types.  
Ben explains, "When we think about the customer bases we're serving, we're working with many different pharmaceutical companies conducting critical and life-changing research. We just announced a partnership with the Parkinson's Foundation so they can help find ways to gather information and data about patients living with Parkinson's disease. But they need that access and data from patients. By working with Tasso, we enable them to have that reach and accessibility." 
"When we're working with various pharmaceutical companies. They're seeing this real need to get subjects into their trials, to ease recruitment, to help make sure they're hitting their recruitment targets. To help make sure that as a patient goes through a clinical trial, they're able to meet all the data points that are needed so that they can have a completed data set for their own submission. And broadly, in that industry, we're seeing this huge shift. It's really exciting that pharma companies, sponsors, and CROs are looking for more tools to provide patients with better access and lower the barrier, lowering the bar for people to participate in these trials."
#Tassoinc #DecentalizedClinicalTrials #DCT #ClinicalTrials #HealthTechnology #HealthTech
tassoinc.com
Listen to the podcast here

 

Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection options to accommodate different lab processes and sample types.  
Ben explains, "When we think about the customer bases we're serving, we're working with many different pharmaceutical companies conducting critical and life-changing research. We just announced a partnership with the Parkinson's Foundation so they can help find ways to gather information and data about patients living with Parkinson's disease. But they need that access and data from patients. By working with Tasso, we enable them to have that reach and accessibility." 
"When we're working with various pharmaceutical companies. They're seeing this real need to get subjects into their trials, to ease recruitment, to help make sure they're hitting their recruitment targets. To help make sure that as a patient goes through a clinical trial, they're able to meet all the data points that are needed so that they can have a completed data set for their own submission. And broadly, in that industry, we're seeing this huge shift. It's really exciting that pharma companies, sponsors, and CROs are looking for more tools to provide patients with better access and lower the barrier, lowering the bar for people to participate in these trials."
#Tassoinc #DecentalizedClinicalTrials #DCT #ClinicalTrials #HealthTechnology #HealthTech
tassoinc.com
Download the transcript here

Chris Darland, President and CEO of Peerbridge Health, discusses technology breakthroughs that enable early, low-cost detection of heart issues with a cardiac monitor that uses AI to analyze heart rhythms over time to detect patterns that may indicate heart failure. The device is based on ECG technology that drives the Holter monitor and delivers a full 12-lead ECG with a volumetric 3D view of the heart. The goal is to reach more patients who may not proactively seek medical attention and provide early intervention and treatment. 
Chris explains, " I think the problem with the current state is largely that it's too late. And I say that to mean that 80% of all heart failure cases today are getting caught after an emergency room visit. So, it's not necessarily that we don't have the tools to find heart failure and the cardiologists and expertise to identify it, but we're not getting it in time. So if you are one of those patients who, let's say, are caught earlier or maybe unfortunately when you come through the ER, a lot of the tools are existing in the hospital. So you'll get an ultrasound, an echo, to get a view of your heart. We'll do an ECG in the hospital and potentially a cardiac MRI. There's a suite of tools available in the acute care setting that can get to this conclusion relatively quickly if you have all the tools right in front of you."
"The nice part about it is it's relatively accepted from a workflow perspective, a tool that's used quite commonly and has become exceedingly convenient over the last five to 10 years. There is a lot of innovation in a handful of companies to make it easy to wear, light, waterproof, etc. And when we think through the innovation we're working through right now, it's essentially using that tool and the output of this ambulatory cardiac monitor that we have in Peerbridge. Then doing some interesting AI advanced diagnostics on top of it to pick up patterns that were maybe lost historically or potentially missed based on signal fidelity of devices that were in the market. Then using those patterns to try to get a head start on heart failure diagnosis as well as a handful of other things we can show they do."
#PeerbridgeHealth #Cardiology #Cardiologists #ECG #HeartHealth #HeartFailure #EarlyDetection #RemotePatientMonitoring
PeerbridgeHealth.com
Listen to the podcast here
 

Chris Darland, President and CEO of Peerbridge Health, discusses technology breakthroughs that enable early, low-cost detection of heart issues with a cardiac monitor that uses AI to analyze heart rhythms over time to detect patterns that may indicate heart failure. The device is based on ECG technology that drives the Holter monitor and delivers a full 12-lead ECG with a volumetric 3D view of the heart. The goal is to reach more patients who may not proactively seek medical attention and provide early intervention and treatment. 
Chris explains, " I think the problem with the current state is largely that it's too late. And I say that to mean that 80% of all heart failure cases today are getting caught after an emergency room visit. So, it's not necessarily that we don't have the tools to find heart failure and the cardiologists and expertise to identify it, but we're not getting it in time. So if you are one of those patients who, let's say, are caught earlier or maybe unfortunately when you come through the ER, a lot of the tools are existing in the hospital. So you'll get an ultrasound, an echo, to get a view of your heart. We'll do an ECG in the hospital and potentially a cardiac MRI. There's a suite of tools available in the acute care setting that can get to this conclusion relatively quickly if you have all the tools right in front of you."
"The nice part about it is it's relatively accepted from a workflow perspective, a tool that's used quite commonly and has become exceedingly convenient over the last five to 10 years. There is a lot of innovation in a handful of companies to make it easy to wear, light, waterproof, etc. And when we think through the innovation we're working through right now, it's essentially using that tool and the output of this ambulatory cardiac monitor that we have in Peerbridge. Then doing some interesting AI advanced diagnostics on top of it to pick up patterns that were maybe lost historically or potentially missed based on signal fidelity of devices that were in the market. Then using those patterns to try to get a head start on heart failure diagnosis as well as a handful of other things we can show they do."
#PeerbridgeHealth #Cardiology #Cardiologists #ECG #HeartHealth #HeartFailure #EarlyDetection #RemotePatientMonitoring
PeerbridgeHealth.com
Download the transcript here